12 Health Care Stocks Moving In Wednesday's Intraday Session
I'm LongbridgeAI, I can summarize articles.During Wednesday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Indaptus Therapeutics (+20.4%), Outlook Therapeutics (+19.9%), and Myomo (+19.84%). Conversely, major losers featured Picard Medical (-32.4%), Aditxt (-31.15%), and Regentis Biomaterials (-29.4%). The list highlights substantial price movements across various market capitalizations in the health care sector.
Gainers
- Indaptus Therapeutics (NASDAQ:INDP) stock increased by 20.4% to $2.44 during Wednesday's regular session. The company's market cap stands at $229.3 million.
- Outlook Therapeutics (NASDAQ:OTLK) shares increased by 19.9% to $0.84. The company's market cap stands at $104.7 million.
- Myomo (AMEX:MYO) shares increased by 19.84% to $1.57. The company's market cap stands at $50.6 million.
- Clover Health Investments (NASDAQ:CLOV) shares increased by 17.36% to $5.04. The company's market cap stands at $2.2 billion.
- ENvue Medical (NASDAQ:FEED) stock increased by 14.89% to $0.86. The market value of their outstanding shares is at $4.5 million.
- Shoulder Innovations (NYSE:SI) shares rose 13.9% to $17.45. The market value of their outstanding shares is at $317.7 million.
Losers
- Picard Medical (AMEX:PMI) stock declined by 32.4% to $0.22 during Wednesday's regular session. The company's market cap stands at $29.8 million.
- Aditxt (NASDAQ:ADTX) stock declined by 31.15% to $0.02.
- Regentis Biomaterials (AMEX:RGNT) shares decreased by 29.4% to $1.7. The company's market cap stands at $12.4 million.
- Silexion Therapeutics (NASDAQ:SLXN) shares declined by 23.27% to $3.2. The company's market cap stands at $1.7 million.
- CervoMed (NASDAQ:CRVO) shares declined by 22.15% to $2.25. The market value of their outstanding shares is at $26.7 million.
- Aptorum Group (NASDAQ:APM) shares fell 19.64% to $0.9. The company's market cap stands at $9.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.